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Introduction: Congenital heart disease (CHD) affects approximately 8 in every 1000 
live births with ventricular septal defect (VSD) being the most common phenotype. VSD is 
thought to arise from genetics and environmental factors, however most of the causes remain 
unknown. It was hypothesized that SMAD7 gene could influence the risk of VSD. SMAD7 is 
a potent antagonist of TGF- signalling pathways and has been found to be involved in 
embryonic cardiovascular development and function in mouse models. However, its role in 
the pathogenesis of VSD in human has yet to be fully understood. Therefore, SMAD7 gene 
was examined in for its susceptibility to VSD in this study. 
 
Objectives: The aims of this study were to screen and identify the genetic variants in 
exon 1 of SMAD7 gene and to determine the association of the genetic variants with VSD in 
Malay population. 
 
Patients and Methods: Peripheral blood samples were collected from 30 non-
syndromic Malay patients with a clinical diagnosis of VSD. From these samples, genomic 
DNAs were extracted before subjected to PCR amplifications using 2 sets of designed 
primers encompassing the exon 1 of SMAD7. Subsequently, re-sequencing was conducted to 
identify and characterize the genetic variants in SMAD7 gene. Observed genetic variants were 
then genotyped in 30 healthy controls using the re-sequencing technique. 
 
Results: A total of 2 genetic variants were identified in both cases and controls, 
comprising one common upstream gene sequence, rs7236774 and one rare synonymous 
sequence, rs368427729. Further analysis on these two genetic variants did not show any 
statistically significance association with the risk of developing VSD. 
 
Conclusion: This case-control study has indicated that the exon 1 of SMAD7 was not 
associated with VSD in Malay population. However, these findings could have been limited 
by small sample size. Therefore, further study in a larger cohort is warranted to yield a 
concrete evidence of this association. 
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ABSTRAK 
 
 
SARINGAN MUTASI EXON 1 GEN SMAD7 DALAM KALANGAN PESAKIT 
MELAYU DENGAN KECACATAN SEPTAL VENTRIKEL 
 
Penyakit jantung kongenital (CHD) menyerang kira-kira 8 orang dalam setiap 1000 
kelahiran hidup dengan kecacatan septal ventrikel (VSD) sebagai fenotip yang paling 
kerap berlaku. Faktor-faktor genetik dan persekitaran dianggap sebagai punca terjadinya 
penyakit VSD, namun sebahagian besar daripada punca-puncanya masih belum 
diketahui. Hipotesis mengatakan bahawa gen SMAD7 boleh mempengaruhi risiko 
berlakunya penyakit VSD. SMAD7 adalah antagonis kepada laluan isyarat TGF- dan ia 
juga dilaporkan terlibat dalam proses pembentukan kardiovaskular embrio dalam model 
tetikus. Walau bagaimanapun, peranannya dalam patogenesis penyakit VSD dalam 
manusia masih belum difahami secara jelas. Oleh itu, kajian ini dijalankan bagi menguji 
kecenderungan gen SMAD7 terhadap penyakit VSD. 
 
Satu kajian kes-kawalan telah dijalankan bagi mengenalpasti hubung kait antara 
SMAD7 dengan penyakit VSD dalam kalangan penduduk Melayu. Exon 1 daripada 
SMAD7 yang mengekod domain fungsian MH1 telah disusun semula melibatkan 30 
 xvii 
 
pesakit VSD bukan sindromik dan 30 individu kawalan. Satu jujukan di bahagian 
pangkal gen yang biasa berlaku, iaitu rs7236774 dan satu urutan sinonim yang jarang 
berlaku, iaitu rs368427729 telah dikenal pasti di dalam kedua-dua kumpulan kes dan 
kawalan. Analisis lanjut mendapati, kedua-dua variasi tidak menunjukkan mana-mana 
hubungkait statistik yang signifikan dengan risiko mendapat VSD.  
 
Kesimpulannya, kajian ini telah menunjukkan bahawa exon 1 daripada gen SMAD7 
tidak mempunyai kaitan dengan VSD dalam populasi Melayu. Walau bagaimanapun, 
hasil kajian ini mungkin dipengaruhi oleh saiz sampel yang kecil. Justeru, kajian lanjut 
dalam saiz sampel yang lebih besar adalah amat perlu untuk mengkaji hubungan gen 
dengan penyakit ini bagi mendapatkan bukti yang lebih kukuh. 
 xviii 
 
ABSTRACT 
 
 
MUTATIONAL SCREENING OF EXON 1 OF SMAD7 IN MALAY PATIENTS 
WITH VENTRICULAR SEPTAL DEFECT 
 
Congenital heart disease (CHD) affects approximately 8 in every 1000 live births with 
ventricular septal defect (VSD) being the most common phenotype. VSD is thought to 
arise from genetics and environmental factors, however most of the causes remain 
unknown. It was hypothesized that SMAD7 gene could influence the risk of VSD. 
SMAD7 is a potent antagonist of TGF- signalling pathways and has been found to be 
involved in embryonic cardiovascular development in mouse models. However, its role 
in the pathogenesis of VSD in human has yet to be fully understood. Therefore, SMAD7 
gene was examined in for its susceptibility to VSD in this study. 
 
A case-control study was conducted to examine whether SMAD7 is associated with 
VSD in Malay population. Exon 1 of SMAD7 which encodes the functional MH1 
domain was re-sequenced in 30 non-syndromic VSD patients and 30 control 
individuals. One common upstream gene sequence, rs7236774 and one rare 
synonymous sequence, rs368427729 were observed in both cases and controls. Further  
 xix 
 
analysis on these two variations did not show any statistically significance association 
with the risk of developing VSD.  
 
In conclusion, this study has indicated that the exon 1 of SMAD7 was not associated 
with VSD in Malay population. However, these findings could have been limited by 
small sample size. Therefore, further study in a larger cohort is warranted to yield a 
concrete evidence of this association. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
1.1 Introduction and overview 
“The heart is the youngest, most diverse, most fluid, most changeable, most versatile 
part of creation” 
Johann Wolfgang Von Goethe (Williams, 1998) 
 
The heart is the first functional organ to form during embryogenesis in order to provide 
adequate nutrients and oxygen to the growing organ systems in a developing foetus. In 
relation to other organs; the heart is unique because it can perform its function 
throughout development. As early as 3 weeks of gestation, the heart is already 
functional although it is far from fully developed (Moore and Persaud, 1998). Several 
major processes such as heart tube formation, looping of the heart, chamber formation, 
valve development and coronary vasculogenesis are necessary for the development of 
heart in its mature form. The whole process involves a precisely orchestrated series of 
molecular and morphogenetic events and it takes about 11 weeks for it to be fully 
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formed (Iaizzo, 2009). Any subtle changes of this process can lead to serious 
consequences in the form of congenital heart disease (CHD).  
 
CHD is one of the leading causes of childhood mortality and morbidity worldwide 
(Richards and Garg, 2010). Despite advances in the patient management, understanding 
of the aetiopathogenesis of CHD remains incomplete. Advances have been made in 
understanding the molecular basis of CHD, including the identification of signalling 
molecules, transcriptional regulators and structural genes. Animal models have 
significantly aided in identifying the molecular mechanisms of CHD, however more 
human-based research is needed to better understand the pathogenesis of human CHD. 
Understanding the molecular aspects of heart development will help to identify the risk 
of having CHD with screening tests, improve clinical diagnosis with diagnostic tests, 
provide accurate genetic counselling and identify potential therapeutic interventions. 
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1.2 Cardiogenesis 
The cardiovascular system is the first functional major system in the embryo. The 
primordial heart and vascular system develop in the cardiogenic region of the mesoderm 
from week 3 of gestation (Figure 1.1).  
 
1.2.1 Primordial heart tube 
Beginning at day 13 of human development, a primitive streak starts to develop. Three 
primary germ layers; ectoderm, mesoderm and endoderm are formed around day 15 of 
gestation. The primordium of the heart is mainly derived from the splanchnic mesoderm 
which appears around day 18 of embryonic development. Primitive streak cells migrate 
to an anterior and lateral position and then fuse to form a cardiac crescent. Lateral 
folding of the embryo causes the cells of the crescent to coalesce along the ventral 
midline to form a single primitive heart tube. As the folding process continues, the heart 
tube comes to lie ventrally to the foregut. The heart tube continues to develop to form 
five distinct regions; truncus arteriosus, bulbous cordis, primitive ventricle, primitive 
atrium and sinus venosus. This is followed by the heart looping process whereby the 
quick development of bulbous cordis and ventricle are causing the heart tube to bend 
upon itself and to form a U-shaped bulboventricular loop. As a result, the atrium and 
sinus venosus end up lying dorsal to the truncus arteriosus, bulbous cordis and ventricle. 
The whole process completes by day 28 of embryonic development (Moore and 
Persaud, 1998). 
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1.2.2 Partitioning of primordial heart and formation of heart chambers 
This process involves formation of the atrioventricular (AV) canal, primordial atrium 
and primordial ventricle; which occur concurrently from the end of the fourth week till 
late fifth week. 
 
At the end of the fourth week, two endocardial cushions appear from the dorsal and 
ventral walls of AV canal. These endocardial cushions fuse and form right and left AV 
canals, partially separating the atrium from the ventricle. 
 
Septum primum appears at the end of the fourth week and grows towards the fusing 
endocardial cushions, thereby partially dividing the primordial atrium into right and left 
atria. Foramen primum resulted from this process, which is located at the area between 
the endocardial cushion and the free edge of the septum primum. The extensions of the 
endocardial cushions grow along the margin of the septum primum and eventually close 
the ostium primum. Coalescence of these perforations results in formation of the septum 
secundum. This septum grows towards the endocardial cushion, gradually overlapping 
the septum primum causing the formation of the foramen ovale. The foramen ovale will 
only close after birth, resulting in a complete partition of the atria. 
 
A muscular interventricular (IV) septum is also developed at the end of fourth week, 
located in the floor of ventricle near its apex. While growing, a gap is formed between 
the IV septum and the endocardial cushion, called the IV foramen. The IV foramen 
usually closes by the end of the seventh week as a result of fusion of bulbar ridges and 
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the endocardial cushion. This fusion also results in the formation of the membranous 
part of the IV septum. The whole process causes the division of the primordial ventricle 
into right and left ventricles, which is completed by the end of week 7 (Moore and 
Persaud, 1998). 
 
1.2.3 Partitioning of the bulbous cordis and truncus arteriosus 
Early in the fifth week of development, ridges develop in the truncus arteriosus and are 
continuous with the bulbar ridges. Both bulbar and truncal ridges undergo 180 degree 
spiralling motion before fusing, resulting in the formation of a spiral aorticopulmonary 
septum. This septum eventually creates the aorta and the pulmonary trunk. The whole 
process completes by the end of week 7 (Moore and Persaud, 1998).  
 
1.2.4 Development of heart valves 
Semilunar valves begin to form at late fifth to early sixth week of development, just 
before the partitioning of truncus arteriosus completes. The semilunar valves develop 
from three swellings of subendocardial tissue located around the openings of the aorta 
and pulmonary trunk. These swellings eventually reshape to form three thin-walled 
cusps. The atrioventricular valves also formed in the similar manner as aforementioned. 
These valves develop from swellings of the tissue around the AV canals (Moore and 
Persaud, 1998). 
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Figure 1.1 Cardiovascular developments 
  Adapted from Yamagishi et al. (2009) 
    
Legend: 
 AV = atrioventricular 
 AP = aortopulmonary 
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1.3 Congenital Heart Disease (CHD) 
Congenital (con, together; genitus, born) heart disease is defined as a gross structural 
abnormality of the heart or intrathoracic great vessels that is actually or potentially of 
functional significance (Mitchell et al., 1971). 
 
1.3.1 Epidemiology of CHD 
CHD is the most frequently occurring birth defect, comprising approximately 40% of all 
congenital defects (Romano‐Zelekha et al., 2001). It is the leading non-infectious cause 
of worldwide neonatal and infants mortality. The reported birth prevalence of CHD is 
approximately 8 in 1000 live births worldwide (Bernier et al., 2010). Geographical 
distributions influence the birth prevalence of CHD. Compared to other continents, Asia 
is reported to show the highest CHD birth prevalence with 9.3 per 1000 live births, 
followed by Europe with 8.2 per 1000 live births. Africa shows the lowest birth 
prevalence of CHD, with only 1.9 per 1000 live births (van der Linde et al., 2011).                                      
 
The estimated frequency of severe heart defects in live born infants is 0.6% (Hoffman 
and Kaplan, 2002; Pradat et al., 2003); however, the incidence is higher if less serious 
and mild defects are included which account for nearly 0.9% of live born infants 
(Hoffman and Kaplan, 2002; Tutar et al., 2005). For instance, the incidence of bicuspid 
arterial valve (BAV), which often goes undetected until late middle age; is nearly 2% 
(Tutar et al., 2005). To top it all, the percentage would be even higher if the proportion 
of pregnancies which do not continue to term were included, as there is a 10-fold higher 
rate of CHD in foetuses compared to live born infants (Salvador et al., 2005). 
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According to Hoffman and Kaplan (2002), the estimated rate of severe cardiovascular 
malformations has not differed much from one study to the other over the last 50 years. 
However, there is an apparent increase in the frequency over the last two decades, 
attributed largely by the increased use of echocardiography (Hoffman and Kaplan, 
2002; Bosi et al., 2003). The higher prevalence may be caused by changes in diagnostic 
techniques and screening modalities rather than a true increase (van der Linde et al., 
2011). Prior to the echocardiography era, diagnosis of CHD was dependent on physical 
examination, conventional x-rays, surgical findings, death certificates and autopsy 
findings. Medical advancement and evolution not only improved diagnostic approach, 
but also played a role in the outcome and survival of patients with CHD. Before the 
introduction of cardiac surgery in 1939, fewer than 25% of infants born with complex 
CHD survived past their first year of life. However, nowadays more than 90% of such 
infants can survive into adulthood (Warnes, 2005).  
 
1.3.1 (a) Epidemiology of CHD in Malaysia 
To date, there are only limited studies in Malaysia describing the epidemiology, clinical 
presentation and outcome of CHD; despite the significant role of CHD in causing 
mortality. According to the Ministry of Health, there are no local data on the incidence 
of congenital heart defects in Malaysia. Based on the international, particularly Asian 
prevalence of 8 – 9.3 in 1000 live births, with a birth rate of approximately 500,000 per 
annum in Malaysia; it is estimated that about 4,000 to 4650 infants will be born with 
congenital heart defects every year. About one third of these patients have simple 
lesions and will not require any intervention while another two thirds will require 
cardiac intervention or surgery. 
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1.3.2 Classification of CHD 
There are several ways to classify CHD, typically by using a physiological or 
anatomical approach. The physiological approach divides CHD into either cyanotic or 
acyanotic lesions. Cyanosis occurs when there is more than 5 g/dl of deoxygenated 
venous blood. Blood is often shunted to the left heart (right-to-left shunt), systemically 
reducing arterial O2 saturation. One of the most frequent cyanotic heart diseases is 
Tetralogy of Fallot. In the case of acyanotic heart lesion, oxygenated blood from the left 
heart shunts to the right, creating the left-to-right shunt. Ventricular septal defect, atrial 
septal defect and patent ductus arteriosus fall into this category. The anatomical 
approach divides CHD into either simple or complex diseases. One of the preferred 
methods of classifying CHD is by combining both anatomical and physiological 
approach, as shown in Table 1.1. 
 
Apart from the aforementioned methods, another preferred method is by classifying 
CHD based on ICD classification, as shown in Table 1.2. ICD, an acronym for 
International Classification of Diseases, is a set of codes used by healthcare personnel to 
indicate diagnosis for all patients encounters; based World Health Organization (WHO). 
 In ICD-10 (International Statistical Classification of Diseases and Related Health 
Problems, 10th Revision), CHD is grouped as ‘Congenital malformations, deformations 
and chromosomal abnormalities’ in chapter XVII, Q20-Q24. 
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Table 1.1 Classification of CHD, Adapted from Wu and Child (2004) 
Types of CHD 
Left to right shunt 
Atrial septal defect (ASD) 
Ventricular septal defect (VSD) 
Atrioventricular septal defect (AVSD) 
Patent ductus arteriosus (PDA) 
Partial anomalous pulmonary venous drainage 
Outflow obstruction 
Bicuspid aortic valve 
Coarctation of the aorta 
Pulmonary stenosis 
Hypoplastic left heart syndrome 
Cyanosis and decreased pulmonary blood flow 
Tetralogy of Fallot 
Tricuspid atresia 
Pulmonary atresia 
Hypoplasia of right ventricle 
Ebstein’s anomaly 
Cyanosis and increased pulmonary blood flow 
Transposition of great arteries 
Double outlet ventricle 
Double inlet ventricle 
Truncus arteriosus 
Total anomalous pulmonary venous drainage 
Cyanosis and increased pulmonary vascular resistance 
VSD with Eisenmenger syndrome 
ASD with Eisenmenger syndrome 
PDA with Eisenmenger syndrome 
Anomalies of major blood vessels 
Congenitally corrected transposition of the great arteries 
Coronary artery anomalies  
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Table 1.2 ICD-10 classification of CHD (Source: WHO) 
Code Description 
Q20 Congenital malformations of cardiac chambers and connections 
Common arterial trunk: Persistent truncus arteriosus 
Double outlet right ventricle: Taussig-Bing syndrome 
Double outlet left ventricle 
Discordant ventriculoarterial connection: Transposition of great vessels 
Double inlet ventricle 
Discordant atrioventricular connection: Corrected transposition 
Isomerism of atrial appendages 
 
Q21 Congenital malformations of cardiac septa 
Ventricular septal defect 
Atrial septal defect 
Atrioventricular septal defect 
Tetralogy of Fallot 
Aortopulmonary septal defect 
Other congenital malformation of of cardia septa: Eisenmenger's syndrome 
 
Q22 Congenital malformations of pulmonary and tricuspid valves 
Pulmonary valve atresia 
Congenital pulmonary valve stenosis 
Congenital pulmonary valve insufficiency 
Other congenital malformations of pulmonary valve 
Congenital tricuspid stenosis: Tricuspid atresia 
Ebstein's anomaly 
Hypoplastic right heart syndrome 
Other congenital malformations of tricuspid valve 
Congenital malformation of tricuspid valve, unspecified 
 
Q23 Congenital malformations of aortic and mitral valves 
Congenital stenosis of aortic valve 
Congenital insufficiency of aortic valve 
Congenital mitral stenosis 
Congenital mitral insufficiency 
Hypoplastic left heart syndrome 
Other congenital malformations of aortic and mitral valves 
Congenital malformation of aortic and mitral valves, unspecified 
 
Q24 Other congenital malformations of heart 
Dextrocardia, Laevocardia 
Cor triatriatum 
Pulmonary infundibular stenosis 
Congenital subaortic stenosis 
Malformation of coronary vessels 
Congenital heart block 
Other specified congenital malformations of heart 
Congenital malformation of heart, unspecified 
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1.3.3 Aetiology of CHD 
CHD is thought to be resulting from multiple factors that cause disruptions at various 
points along the cardiac developmental pathway. Some genetic defects and certain 
environmental factors have been identified contributing to the abnormal formation of 
the heart. While genetic and environmental causes of CHD are well recognized, the 
majority of the causes of CHD remain unknown. Evidence from familial aggregation 
studies, chromosomal studies and animal studies indicate that CHD is caused by 
‘multifactorial inheritance’, which is due to a combination of both genetic and 
environmental factors, where the environmental factor interacts with a genetic 
predisposition in an individual (Nora, 1968; Gelb, 2004; Garg, 2006). It is estimated 
that more than 85% of CHDs result from a complex interaction between foetal – 
maternal exposures and genetic susceptibilities (Botto and Correa, 2003). Even in 
families with multiple affected individuals, environmental factors may be needed for the 
development of CHD. 
 
1.3.3 (a) Environmental factors 
Environmental factors of CHD are broadly meant to include all factors external to the 
genetic architecture of the mother and the developing foetuses. Potential environmental 
agents include infections, chemical and pharmacological exposures, physical factors as 
well as maternal nutrition. Human exposure to environmental agents during the three 
months before pregnancy and weeks 2 through 7 of gestation are most likely to result in 
cardiac structural abnormalities, therefore; this segment is focused on factors that 
influence cardiac development during this period (Jenkins et al., 2007). Table 1.3 
summarized the potential environmental factors associated with CHD. 
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These factors may exert effect directly on the foetus or indirectly via the mother. 
However, the exact mechanisms by which these environmental agents disrupt 
embryogenesis and cause defects still remain to be elucidated. Depending on the 
maternal or foetal genotype, environmental exposure may differently affect the heart 
development; for example, exposure to the different level of the environmental factor 
might result in different phenotype. Furthermore, it is likely that some genetic 
polymorphisms are more environmentally sensitive resulting phenotypic heterogeneity 
(Wyszynski et al., 2010). 
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Table 1.3 Environmental factors and associated CHD  
  Adapted from Jenkins et al. (2007) and Mahler and Butcher (2011) 
Factors Associated defects 
Maternal Illness 
Pregestational diabetes Conotruncal defects 
Laterality and looping 
Transposition of the great arteries 
Septal defects 
Hypoplastic left heart syndrome 
Outflow tract defects 
Patent ductus arteriosus 
Phenylketonuria Tetralogy of Fallot 
Coarctation of the aorta 
Febrile illness Conotruncal defects 
Right-sided obstructive defects 
Tricuspid atresia 
Left-sided obstructive defects 
Coarctation of the aorta 
Ventricular septal defect 
Maternal Infections 
Influenzae Transposition of the great arteries 
Right-sided obstructive defects 
Left-sided obstructive defects 
Coarctation of the aorta 
Ventricular septal defect 
Rubella Patent ductus arteriosus 
Peripheral pulmonary artery stenosis 
Atrial septal defect 
Ventricular septal defect 
Maternal therapeutic drug exposure 
Indomethacin tocolysis Patent ductus arteriosus 
Ibuprofen Transposition of the great arteries 
Ventricular septal defect 
Bicuspid aortic valve 
Anticonvulsants Any defects 
Thalidomide Any defects 
Maternal non-therapeutic drug exposure 
Vitamin A Outflow tract defects 
Cranial neural crest defects (cardiac and 
noncardiac) 
Pulmonic stenosis 
Recreational drugs (Marijuana 
and cocaine) 
Atrial septal defect 
Ventricular septal defect 
Pulmonary stenosis 
Ebstein’s anomaly 
Others 
Organic solvents Any defects 
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1.3.3 (b) Genetic factors 
CHD may occur as an isolated defect (non-syndromic) or be associated with other birth 
defects and dysmorphism (syndromic). Isolated defects are the most prevalent form of 
CHD. While most CHD patients do not have other defects, studies have shown that it 
can occur in the setting of other multiple congenital anomalies, developmental 
abnormalities or growth abnormalities and be a part of a syndrome (Bernstein, 2004; 
Pierpont et al., 2007). The pathogenesis of and risk factors for CHD in a syndromic 
child are likely to be different from those in a child without accompanying syndrome. A 
number of studies have considered infants with a syndrome to be a highly susceptible 
population, providing insight into the risk factors of heart defects (Kerstann et al., 
2004).   
 
Genetic factors of CHD can be classified according to the underlying genetic 
mechanism. Syndromic CHD can be due to chromosomal, single gene or unknown 
causes (Fahed and Nemer, 2012), whereas non-syndromic CHD is more likely to be 
caused by single gene mutation, genomic imbalances and complex inheritance 
(Wyszynski et al., 2010). Approximately 20% of CHD is associated with a 
chromosomal abnormality, a congenital syndrome or a single gene mutation with 
Mendelian inheritance pattern (Pierpont et al., 2007; Warnes et al., 2008). However, for 
the other 80% of non-syndromic and sporadic CHD cases, the underlying genetic 
mechanisms are still poorly understood.  
 
 
16 
 
1.3.3 (b) (i) Chromosomal abnormality and CHD 
CHD of chromosome abnormality can either be due to chromosome dosage disorders, 
large chromosomal deletions or small micro-deletions (Fahed and Nemer, 2012). A 
recent population study by Hartman et al. (2011) has identified chromosome 
abnormalities in 12.3% of infants with CHD. The most likely chromosome abnormality-
associated CHDs are interrupted aortic arch (69.2%), atrioventricular septal defect 
(67.2%) and double-outlet right ventricle (33.3%). (Hartman et al., 2011).  
 
Approximately 30% of children with a chromosomal abnormality have CHD (Pierpont 
et al., 2007). The most common chromosomal abnormalities are trisomy 21, trisomy 18, 
22q11.2 deletion and trisomy 13. Table 1.4 listed some chromosomal abnormalities 
with the corresponding CHD. 
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Table 1.4 Chromosomal abnormalities and CHD 
  Adapted from (Richards and Garg, 2010) 
Diseases of chromosomal abnormalities Types of CHD 
 
 
Trisomy 21 
(Down Syndrome) 
 
Atrial septal defect 
Ventricular septal defect 
Atrioventricular septal defect 
Tetralogy of Fallot 
 
 
Trisomy 18 
(Edward Syndrome) 
Atrial septal defect 
Ventricular septal defect 
Patent ductus arteriosus 
Tetralogy of Fallot  
Double outlet right ventricle 
Coarctation of aorta 
Bicuspid aortic valve 
 
 
Trisomy 13 
(Patau Syndrome) 
Atrial septal defect 
Ventricular septal defect 
Patent ductus arteriosus 
Hypoplastic left heart syndrome 
 
 
Monosomy X 
(Turner Syndrome) 
Coarctation of aorta 
Bicuspid aortic valve 
Aortic stenosis 
Hypoplastic left heart syndrome 
 
 
47, XXY 
(Klinefelter Syndrome) 
Patent ductus arteriosus 
Atrial septal defect 
Mitral valve prolapsed 
 
 
22q11.2 deletion 
(DiGeorge Syndrome) 
Interrupted aortic arch type B 
Aortic arch anomalies 
Truncus arteriosus 
Tetralogy of Fallot 
 
 
7q11.23 deletion 
(Wlliams-Beuren Syndrome) 
Supravalvular aortic stenosis 
Peripheral pulmonic stenosis 
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1.3.3.(b) (ii) Single gene mutation and CHD 
The majority of CHD cases is thought to occur due to a gene mutation; suggested by 
early observation of Mendelian inheritance in familial CHD and the involvement of 
micro and macro deletions in chromosomal regions resulting in CHD with other 
manifestation. Advancement in gene sequencing and other techniques have helped to 
identify molecular genetic causes of CHD. Many genes have been found to be involved 
in the complex process of heart development in animal models, however few have 
shown an association with CHD in humans.  
 
Some of the identified genes are associated with non-syndromic CHD and others with 
syndromic CHD (Wessels and Willems, 2010; Fahed and Nemer, 2012). In syndromic 
and non-syndromic cases, CHD can occur due to mutations in more than one gene 
(genetic heterogeneity) and mutations in a single gene can result in variable CHDs 
(phenotypic heterogeneity). These genes encode for agents of the heart developmental 
programme involving numerous pathways with cross communications, ligand-receptor 
interactions, complex signal transductions, and a network of transcription factors that 
regulate the expression of cardiac specific genes. Any disruption of these genes will 
result in cardiac defects. Table 1.5 and Table 1.6 show the association of single gene 
defects with syndromic and non-syndromic CHD respectively. Of all genes identified, 
three categories of genes comprise the majority of the known genetic causes of CHD. 
Those groups are GATA transcription factors (GATA4, GATA5, and GATA6), Homebox 
transcription factors (NKX2-5 and NKX2-6), and T-box transcription factors (TBX1, 
TBX5, and TBX20) (Fahed and Nemer, 2012). Genes from these categories interact to 
regulate the expression of downstream genes involved in heart development.  
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Table 1.5 Single gene defects and syndromic CHD 
  Adapted from Pierpont et al. (2007) and Richards and Garg (2010) 
Syndromes Types of CHD Causal gene(s) 
 
Noonan syndrome 
 
Pulmonic valvular stenosis 
Atrioventricular septal defect  
Hypertrophic cardiomyopathy 
Coarctation of aorta 
Tetralogy of Fallot 
 
 
PTPN11 
KRAS 
RAF1  
SOS1 
Alagille syndrome 
 
Pulmonic valvular stenosis 
Tetralogy of Fallot 
Atrial septal defect 
Peripheral pulmonary stenosis 
 
JAG1 
NOTCH2 
Holt-Oram 
syndrome 
All septal defects 
Progressive atrioventricular conduction 
system disease 
 
TBX5 
Char syndrome 
 
Patent ductus arteriosus TFAP2b 
CHARGE 
syndrome 
Atrial septal defect 
Ventricular septal defect 
Atrioventricular canal defects 
Tetralogy of Fallot 
Coarctation of aorta 
Patent ductus arteriosus 
 
CHD7 
SEMA3E  
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Table 1.6 Single gene defects and non-syndromic CHD 
  Adapted from Garg (2006) and Fahed and Nemer (2012) 
Causal gene(s) Types of CHD 
NKX2.5 Atrial septal defect 
Atrioventricular conduction delay 
Tetralogy of Fallot  
Tricuspid valve abnormalities 
 
GATA4 Atrial septal defect 
Ventricular septal defect 
 
MYH6 Atrial septal defect 
Hypertrophic cardiomyopathy 
 
BMPR2 Cardiac septation defects associated with pulmonary 
hypertension 
 
CRELD1, ALK2 Endocardial cushion defects 
 
NOTCH1 Bicuspid aortic valve 
Early valve calcification 
 
PROSIT-240 Transposition of the great arteries 
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1.4 Ventricular septal defect (VSD) and SMAD7 gene 
 
1.4.1 VSD 
VSD is the most common congenital heart defect at birth (Hoffman and Kaplan, 2002) 
accounting for 25% of all congenital heart defects and occurring in approximately 3.0 to 
3.5 infants per 1000 live births (Warnes et al., 2008). Previous studies have reported 
that there is a high incidence of spontaneous closure of small VSDs, therefore the 
incidence is much less in older infants and in adults (Du et al., 1998). 
 
VSD is classified in regards to the anatomic landmarks of the ventricular septum. The 
ventricular septum is a curvilinear, three-dimensional partition that divides the heart 
into five components: membranous, infundibular (or subarterial), inlet, muscular (or 
trabecular) and the atrioventricular septum (Figure 1.2). Incomplete fusion or deficit 
growth of any of these components will lead to VSD. Based on the Congenital Heart 
Surgery Nomenclature and Database Project (Jacobs et al., 2000), VSD is classified into 
multiple, type 1, type 2, type 3, type 4, Gerbode type and secondary VSD; as shown as 
in Table 1.7. 
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Figure 1.2 Positions of different ventricular septal defect 
  Adapted from Ammash and Warnes (2001) 
 
Legends: 
1 membranous  
2 subarterial or supracristal  
3 muscular or trabecular 
4 inlet or canal 
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Table 1.7 Classification of VSD, based on the Congenital Heart Surgery 
Nomenclature and Database Project (Jacobs et al., 2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VSD subtypes Synonyms 
 
Type 1 
 
Conal septal defect 
Subarterial 
Supracristal 
Subpulmonary 
Infundibular 
 
Type 2 Perimembranous 
Paramembranous 
Conoventricular  
 
Type 3 Inlet 
Atrioventricular canal type 
 
Type 4 Muscular 
 
Gerbode type Atrioventricular 
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Of all subtypes of VSD, membranous type is the most commonly seen defect, account 
for 80% of the cases. It is located inferior to the aortic valve and bordering the septal 
leaflet of the tricuspid valve. It can extend into the adjacent muscular septum, termed 
perimembranous VSD; which often associated with aneurysm of the septal leaflet of the 
triscuspid valve and aortic regurgitation (Warnes, 2009). 
 
Infundibular VSD, which account for 5-8% of isolated VSDs in the United States but 
30% in Southeast Asia; is a defect that lies beneath the pulmonic valve and 
communicates with the right ventricle outflow tract above the supraventricular crest. It 
is associated with aortic regurgitation secondary to the prolapse of the right aortic cusp. 
Aortic regurgitation can help to reduce the size of the defect but no spontaneous closure 
is reported (Warnes, 2009). 
 
Inlet VSD lies beneath both atrioventricular valve and extends to the septal leaflet of the 
tricuspid valve. Although it is in close proximity with the atrioventricular valves, they 
are not associated with defects of the mitral or tricuspid regurgitation. About 8-10% of 
VSDs are of this type. Inlet VSD is often seen in Down syndrome patients (Warnes, 
2009). 
 
Muscular VSD is entirely bounded by the muscular septum and represents 5-20% of all 
defects. The defect can either be small or large, single or multiple. The term Swiss-
cheese septum has been used to describe multiple muscular VSDs (Warnes, 2009).  
 
